Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Lenalidomide After Reduced Intensity Allogeneic Transplantation for Multiple Myeloma
2009-012033-30Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by University Hospitals Birmingham. Primary endpoint: Progression-free survival at 2 years. Started Aug 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-012033-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012033-30.